Eisai announced results from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27%.
The Biogen Inc., headquarters in Cambridge. Biogen released a surprisingly low 2022 forecast Thursday, Feb. 3, 2022, as the drugmaker deals with sluggish sales from an Alzheimer’s treatment initially hailed as a potential breakthrough drug.
Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s. Eisai Co. Ltd. said it would discuss full results from the research at a conference in late November. It also plans to publish its findings in a peer-reviewed medical journal. The initial results appear to be “quite robust” and will likely support regulatory approval, Mizuho Securities analyst Graig Suvannavejh said in a research note.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
2021 Chevrolet Silverado Yenko Off Road Is an 800-HP TRX ChallengerThe 2021 Chevrolet Silverado Yenko Off Road brings the Yenko touch to the modern Silverado. The 800-hp truck sports engine, suspension, and exterior mods.
Lire la suite »
At WORTHLESSSTUDIOS, ‘1-800 Happy Birthday’ Honors Black and Brown Victims of Police ViolenceArtist Mohammad Gorjestani’s hope for the exhibition, on through January 16, is that it reminds people that every victim had a life before it was stolen.
Lire la suite »
Alzheimer's drug study yields positive results, say makers Eisai and BiogenAn experimental Alzheimer's drug made by Eisai Co. Ltd. and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs.
Lire la suite »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Lire la suite »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Lire la suite »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Lire la suite »